{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477166482
| IUPAC_name = ''cis''-(+)-[2-(2-Dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2-azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate
| image = Diltiazem structure.svg
| width =
| image2 = Diltiazem ball-and-stick.png
<!--Clinical data-->
| tradename = Cardizem, Dilacorxr
| Drugs.com = {{drugs.com|monograph|diltiazem-hydrochloride}}
| MedlinePlus = a684027
| legal_US = Rx-only
| pregnancy_US = C
| routes_of_administration = [[Mouth|Oral]]
<!--Pharmacokinetic data-->
| bioavailability = 40%
| metabolism = [[Hepatic]]
| elimination_half-life = 3–4.5 hours
| excretion = [[Kidney|Renal]]<br>[[Bile|Biliary]]<br>[[Mammary gland|Lactic]] (in lactating females)
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 42399-41-7
| ATC_prefix = C05
| ATC_suffix = AE03
| ATC_supplemental = {{ATC|C08|DB01}}
| PubChem = 39186
| IUPHAR_ligand = 2298
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00343
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 35850
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = EE92BBP03H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07845
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 101278
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 23
<!--Chemical data-->
| C=22 | H=26 | N=2 | O=4 | S=1
| molecular_weight = 414.519 g/mol
| SMILES = O=C2N(c3c(S[C@@H](c1ccc(OC)cc1)[C@H]2OC(=O)C)cccc3)CCN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HSUGRBWQSSZJOP-RTWAWAEBSA-N
}}

'''Diltiazem''' ([[International Nonproprietary Name|INN]]) ({{IPAc-en||d|ɪ|l|ˈ|t|aɪ|ə|z|ɛ|m}}) is a [[Calcium_channel_blocker#Non-dihydropyridine|nondihydropyridine]] (non-DHP) [[calcium channel blocker]] used in the treatment of [[hypertension]], [[angina pectoris]], and some types of [[arrhythmia]]. It relaxes the [[smooth muscles]] in the walls of [[arteries]], which opens (dilates) the arteries, allows blood to flow more easily, and lowers [[blood pressure]]. Additionally, it lowers blood pressure by acting on the heart itself to reduce the rate, strength, and [[Electrical conduction system of the heart|conduction speed]] of each beat.

It is also used [[off-label]] as an effective preventive medication for [[migraine]]. It is a class 3 [[antianginal]] drug, and a class IV [[antiarrhythmic]]. 

Diltiazem is metabolized by and acts as an [[Enzyme inhibitor|inhibitor]] of the [[CYP3A4]] [[enzyme]] which can cause it to interact with a variety of other medications.

==Mechanism==
[[File:000197lg cardizem 180mg.jpg|left|thumb|180mg Cardizem capsule]]
Diltiazem is a potent [[vasodilator]], increasing blood flow and variably decreasing the [[heart rate]] via strong depression of [[A-V node]] conduction. Its pharmacological activity is somewhat similar to [[verapamil]], another nondihydropyridine (non-DHP) calcium channel blocker.<ref>{{cite journal |pages=145–53 |doi=10.1111/j.1472-8206.1999.tb00333.x |title=The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem |year=1999 |last1=O'Connor |first1=Stephen E. |last2=Grosset |first2=Alain |last3=Janiak |first3=Philip |journal=Fundamental & Clinical Pharmacology |volume=13 |issue=2 |pmid=10226758}}</ref> Chemically, it is based upon a [[1,4-thiazepine]] [[Ring (chemistry)|ring]], making it a [[Calcium channel blocker#Benzothiazepine|benzothiazepine]]-type calcium channel blocker.

It is a vasodilator of [[Coronary circulation|coronary]] and [[peripheral vessels]], which reduces [[peripheral resistance]] and [[afterload]], though not as potent as the [[dihydropyridine]] (DHP) calcium channel blockers.  This results in minimal reflexive [[Sympathetic nervous system|sympathetic]] changes.

Diltiazem has negative [[inotropic]], [[chronotropic]], and [[dromotropic]] effects. This means diltiazem causes a decrease in [[heart muscle contractility]] – how strong the beat is, lowering of heart rate – due to slowing of the [[sinoatrial node]], and a slowing of conduction through the [[atrioventricular node]] – increasing the time needed for each beat. Each of these effects results in reduced [[oxygen consumption]] by the heart, reducing angina symptoms. These effects also reduce blood pressure by causing less blood to be pumped out.

==Nontherapeutic effects and toxicities==
A reflex sympathetic response, caused by the [[peripheral dilation]] of vessels and the resulting drop in blood pressure, works to counteract the negative inotropic, chronotropic and dromotropic effects of diltiazem. Undesirable effects include [[hypotension]], [[bradycardia]], [[dizziness]], and [[Flushing (physiology)|flushing]].<ref>{{cite journal |pages=196–200 |doi=10.1016/S0196-0644(05)80202-1 |title=A one-year evaluation of calcium channel blocker overdoses: Toxicity and treatment |year=1993 |last1=Ramoska |first1=E |last2=Spiller |first2=H |last3=Winter |first3=M |last4=Borys |first4=D |journal=Annals of Emergency Medicine |volume=22 |issue=2 |pmid=8427431}}</ref>

==Indications==
The drug is indicated for angina:
* [[Stable angina]] (exercise-induced) – diltiazem increases [[coronary blood flow]] and decreases [[myocardial]] [[oxygen consumption]], secondary to decreased peripheral resistance, heart rate, and contractility.<ref name="Calcium antagonists">{{cite journal |pages=34–57 |doi=10.1016/j.pcad.2004.04.006 |title=Calcium antagonists |year=2004 |last1=Grossman |first1=Ehud |last2=Messerli |first2=Franz H. |journal=Progress in Cardiovascular Diseases |volume=47 |pmid=15517514 |issue=1}}</ref><ref>{{cite journal |pages=765–76 |doi=10.1517/14656566.6.5.765 |title=Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris |year=2005 |last1=Claas |first1=Steven A |last2=Glasser |first2=Stephen P |journal=Expert Opinion on Pharmacotherapy |volume=6 |issue=5 |pmid=15934903}}</ref>
* [[Variant angina]] – it is effective owing to its direct effects on [[coronary dilation]].
* [[Unstable angina]] ([[preinfarction]], [[Heart_murmur#Classification|crescendo]]) – diltiazem may be particularly effective if the underlying mechanism is [[vasospasm]].

For [[supraventricular tachycardia]]s ([[PSVT]]), diltiazem appears to be as effective as [[verapamil]] in treating [[Reentry (neural circuitry)|re-entrant]] supraventricular tachycardia.<ref>{{cite journal |pages=1874–79 |doi=10.1097/00003246-200110000-00004 |title=Diltiazem to treat sinus tachycardia in critically ill patients: A four-year experience |year=2001 |last1=Gabrielli |first1=Andrea |last2=Gallagher |first2=T. James |last3=Caruso |first3=Lawrence J. |last4=Bennett |first4=Neil T. |last5=Layon |first5=A. Joseph |journal=Critical Care Medicine |volume=29 |issue=10 |pmid=11588443}}</ref>

[[Atrial fibrillation]]<ref name="pmid11171729">{{cite journal |pages=502–06 |doi=10.1378/chest.119.2.502 |title=Acute Ventricular Rate Control in Atrial Fibrillation : IV Combination of Diltiazem and Digoxin vs IV Diltiazem Alone |year=2001 |last1=Wattanasuwan |first1=N. |journal=Chest |volume=119 |issue=2 |pmid=11171729 |last2=Khan |first2=IA |last3=Mehta |first3=NJ |last4=Arora |first4=P |last5=Singh |first5=N |last6=Vasavada |first6=BC |last7=Sacchi |first7=TJ}}</ref> or [[atrial flutter]]  is another indication.  The initial [[Bolus (medicine)|bolus]] should be 0.25&nbsp;mg/kg, [[intravenous]] (IV).

Because of its [[vasodilatory]] effects, diltiazem is useful for treating [[hypertension]]. Calcium channel blockers are well tolerated, and especially effective in treating low-[[renin]] hypertension.<ref>{{cite journal |pages=621–29; quiz 630–1 |doi=10.1111/j.1524-6175.2004.03683.x |title=The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension |year=2004 |last1=Basile |first1=Jan |journal=The Journal of Clinical Hypertension |volume=6 |issue=11}}</ref>

==Contraindications and precautions==
* In [[congestive heart failure]], patients with reduced ventricular function may not be able to counteract the inotropic and chronotropic effects of diltiazem, the result being an even higher compromise of function.
* With [[Heart block|SA node or AV conduction disturbances]], the use of diltiazem should be avoided in patients with SA or AV nodal abnormalities, because of its negative chronotropic and dromotropic effects.
* [[Hypotension|Low blood pressure]] patients, with [[systolic]] blood pressures below 90&nbsp;mm [[Mercury (element)|Hg]], should not be treated with diltiazem.
* Diltiazem may paradoxically increase ventricular rate in patients with [[Wolff-Parkinson-White syndrome]] because of [[accessory conduction pathways]].

Diltiazem is relatively contraindicated in the presence of [[sick sinus syndrome]], [[atrioventricular node]] conduction disturbances, [[bradycardia]], impaired [[left ventricle]] function, [[peripheral artery occlusive disease]], and [[chronic obstructive pulmonary disease]].

==Drug interactions==
Because of its inhibition of [[hepatic]] [[cytochromes]] [[CYP3A4]], [[CYP2C9]] and [[CYP2D6]], there are a significant number of drug interactions, more than can be listed here.<ref name="dilt-inhibit1">{{cite journal|pmid=17655375 |title=General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs|year=2007|last1=Ohno|first1=Y|last2=Hisaka|first2=A|last3=Suzuki|first3=H|volume=46|issue=8|pages=681–96|journal=Clinical pharmacokinetics|doi=10.2165/00003088-200746080-00005}}</ref> Some of the more important interactions are listed below.

===Beta-blockers===
Intravenous diltiazem should be used with caution with beta-blockers because, while the combination is most potent at reducing heart rate, there are rare instances of [[Cardiac arrhythmia|dysrhythmia]] and [[First degree AV block|AV node block]].<ref>{{cite journal |pages=556–9 |doi=10.1097/00005344-200004000-00007 |title=Cardiovascular Adverse Drug Reaction Associated with Combined β-Adrenergic and Calcium Entry-Blocking Agents |year=2000 |last1=Edoute |first1=Yeouda |last2=Nagachandran |first2=Pradeep |last3=Svirski |first3=Boris |last4=Ben-Ami |first4=Haim |journal=Journal of Cardiovascular Pharmacology |volume=35 |issue=4 |pmid=10774785}}</ref>

===Quinidine===
[[Quinidine]] should not be used concurrently with calcium channel blockers because of reduced clearance of both drugs and potential [[pharmacodynamic]] effects at the SA and AV nodes.<ref>{{cite journal|last=Narimatsu|first=Akihiro|author2=Norio Taira|title=Effects on Atrio-Ventricular Conduction of Calcium-Antagonistic Coronary Vasodilators, Local Anaesthetics and Quinidine Injected into the Posterior and the Anterior Septal Artery of the Atrio-Ventricular Node Preparation of the Dog|journal=Archives of Pharmacology|date=August 1976|volume=294|issue=2|pages=169–77|doi=10.1007/bf00507850}}</ref>

==Potential future indications==
Diltiazem is prescribed off-label by doctors in the US for [[prophylaxis]] of [[cluster headache]]s. Some research on diltiazem and other calcium channel antagonists in the treatment and prophylaxis of migraine is ongoing.<ref name="Calcium antagonists"/><ref>{{cite journal |pmid=1353873 |year=1992 |last1=Montastruc |first1=JL |last2=Senard |first2=JM |title=Médicaments anticalciques et prophylaxie de la migraine |trans_title=Calcium channel blockers and prevention of migraine |language=French |volume=40 |issue=4 |pages=381–88 |journal=Pathologie et Biologie}}</ref><ref>{{cite journal |pmid=1990741 |year=1991 |last1=Kim |first1=KE |title=Comparative clinical pharmacology of calcium channel blockers |volume=43 |issue=2 |pages=583–88 |journal=American family physician}}</ref><ref>{{cite journal |pmid=1970289 |year=1990 |last1=Andersson |first1=KE |last2=Vinge |first2=E |title=Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine |volume=39 |issue=3 |pages=355–73 |journal=Drugs |doi=10.2165/00003495-199039030-00003}}</ref><ref>{{cite journal |pmid=2147612 |year=1990 |last1=Paterna |first1=S |last2=Martino |first2=SG |last3=Campisi |first3=D |last4=Cascio Ingurgio |first4=N |last5=Marsala |first5=BA |title=Evaluation of the effects of verapamil, flunarizine, diltiazem, nimodipine and placebo in the prevention of hemicrania. A double-blind randomized cross-over study |volume=134 |issue=2 |pages=119–25 |journal=La Clinica terapeutica}}</ref><ref>{{cite journal |pages=1327–28 |doi=10.1056/NEJM198405173102015 |title=Diltiazem Prophylaxis in Refractory Migraine |year=1984 |journal=New England Journal of Medicine |volume=310 |issue=20 |pmid=6144044 |last1=Smith |first1=R |last2=Schwartz |first2=A}}</ref><ref>{{cite journal |pages=278–83 |doi=10.1111/j.1526-4610.1983.hed2306278.x |title=The Pharmacology of Calcium Channel Antagonists: a Novel Class of Anti-migraine Agents? |year=1983 |last1=Peroutka |first1=Stephen J. |journal=Headache: the Journal of Head and Face Pain |volume=23 |issue=6}}</ref>

Recent research has shown diltiazem is able to reduce [[cocaine cravings]] in drug-addicted [[animal testing|rats]].<ref>[http://www.sciencedaily.com/releases/2008/02/080227155016.htm Common Heart Drug May Reduce Cocaine Cravings]. Sciencedaily.com (2008-02-28). Retrieved on 2012-10-21.</ref> This is believed to be due to the effects of calcium blockers on [[dopamine]]rgic and [[glutamate]]rgic signaling in the brain.<ref>{{cite journal |pages=600–08 |doi=10.1016/j.lfs.2007.06.028 |title=Augmented behavioral response and enhanced synaptosomal calcium transport induced by repeated cocaine administration are decreased by calcium channel blockers |year=2007 |last1=Mills |first1=K |last2=Ansah |first2=T |last3=Ali |first3=S |last4=Mukherjee |first4=S |last5=Shockley |first5=D |journal=Life Sciences |volume=81 |issue=7 |pmid=17689567 |pmc=2765982}}</ref> Diltiazem also enhances the [[analgesic]] effect of [[morphine]] in animal tests, without increasing [[respiratory depression]],<ref>{{cite journal |pages=85–92 |doi=10.1016/S0014-2999(00)00248-X |title=Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys |year=2000 |last1=Kishioka |first1=S |journal=European Journal of Pharmacology |volume=397 |pmid=10844102 |last2=Ko |first2=MC |last3=Woods |first3=JH |issue=1}}</ref> and reduces the development of tolerance.<ref>{{cite journal | last1 = Verma | first1 = V | last2 = Mediratta | first2 = PK | last3 = Sharma | first3 = KK | title = Potentiation of analgesia and reversal of tolerance to morphine by calcium channel blockers | journal = Indian journal of experimental biology | volume = 39 | issue = 7 | pages = 636–42 | year = 2001 | pmid = 12019755 }}</ref>

Diltiazem is also being used in the treatment of [[anal fissures]]. It can be taken orally or [[applied topically]] with increased effectiveness.<ref>{{cite journal |pages=1074–8 |doi=10.1007/BF02234624 |title=A randomized trial of oral vs. topical diltiazem for chronic anal fissures |year=2001 |last1=Jonas |first1=Marion |last2=Neal |first2=Keith R. |last3=Abercrombie |first3=John F. |last4=Scholefield |first4=John H. |journal=Diseases of the Colon & Rectum |volume=44 |issue=8}}</ref> When applied topically, it is made into a cream form using either vaseline or Phlojel. Phlojel absorbs the diltiazem into the problem area better than the vaseline base. It has good short term success rates.<ref>{{cite journal |pages=1411–13 |doi=10.1111/j.1742-1241.2006.00895.x |title=The long-term results of diltiazem treatment for anal fissure |year=2006 |last1=Nash |first1=G. F. |last2=Kapoor |first2=K. |last3=Saeb-Parsy |first3=K. |last4=Kunanadam |first4=T. |last5=Dawson |first5=P. M. |journal=International Journal of Clinical Practice |volume=60 |issue=11 |pmid=16911570}}</ref><ref>{{cite journal |pages=1–6 |doi=10.1007/s00384-007-0384-x |title=The efficacy of diltiazem and glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis |year=2007 |last1=Sajid |first1=M. S. |last2=Rimple |first2=J. |last3=Cheek |first3=E. |last4=Baig |first4=M. K. |journal=International Journal of Colorectal Disease |volume=23 |pmid=17846781 |issue=1}}</ref> Like all nonsurgical treatments of anal fissure, it does not address the long term problem of increased basal anal tone and does not decrease the subsequent recurrence rate that can vary between 40 and 60%.

==References==
{{reflist|35em}}

== External links ==
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Diltiazem U.S. National Library of Medicine: Drug Information Portal – Diltiazem]

{{Antiarrhythmic agents}}
{{Ion channel modulators}}

[[Category:Calcium channel blockers]]
[[Category:Benzothiazepines]]
[[Category:Phenol ethers]]
[[Category:Lactams]]
[[Category:Acetate esters]]
[[Category:Chemical substances for emergency medicine]]